Results 361 to 370 of about 17,175,483 (375)
Some of the next articles are maybe not open access.
Primary generalized AL amyloidosis
Arkhiv patologii, 2021The paper describes an autopsy observation of a 71-year-old male with primary generalized AL amyloidosis lasting about 4 months after its manifestation to the onset of death from hepatic and renal failure. Total damage to the liver and spleen, as well as amyloid deposits in the kidneys, adrenal glands, and pancreas were noted.
B B Saltykov, E A Kogan, P V Atanov
openaire +3 more sources
Macroglossia – not always AL amyloidosis
Amyloid, 2010Abstract Abstract 5007 Introduction: Amyloidosis is characterized by extracellular deposition of abnormal insoluble fibrillar proteins. The two most frequent systemic amyloidoses are the light-chain (AL amyloidosis) and familial transthyretin (ATTR) forms.
John L. Berk +6 more
openaire +4 more sources
Management of AL amyloidosis in 2021+
Amyloid, 2021Pallidini et al. in their review article ‘Management of AL Amyloidosis in 2020’ detail the therapeutic options for patients with this disorder [1].
openaire +3 more sources
Primary amyloidosis (AL) in families
American Journal of Hematology, 1986AbstractWe report the occurrence of immunoglobulin‐related amyloidosis (AL) in three separate families, each family having two members affected. None of the six patients had evidence to suggest the presence of familial amyloidosis (AF). Previously, immunoglobulin‐related amyloidosis (AL) was considered to be a sporadic disease process.
Robert A. Kyle +2 more
openaire +2 more sources
Sudden Death by AL Amyloidosis
American Journal of Forensic Medicine & Pathology, 2023Abstract We report the case of a young female that died due to systemic amyloidosis.
Christian, Perez, Kristy, Waite
openaire +2 more sources
The epidemiology of AL and AA amyloidosis
Baillière's Clinical Rheumatology, 1994The limited available epidemiological information on AL amyloidosis suggests that there may be differences between population-based studies and case series data with respect to variables such as age and racial patterns. Much more work in this area is required before specific aetiologic hypotheses can be tested.
Robert W. Simms +2 more
openaire +3 more sources
Hematology/Oncology Clinics of North America, 2020
This article focuses on the patient experience of AL amyloidosis; the unique challenges that patients face from the journey to diagnosis through treatment; and management of this complex multisystemic disease. Included are descriptions of the most significant AL amyloidosis symptoms as well as addressing burden of disease, including financial concerns,
Mackenzie Boedicker, Isabelle Lousada
openaire +2 more sources
This article focuses on the patient experience of AL amyloidosis; the unique challenges that patients face from the journey to diagnosis through treatment; and management of this complex multisystemic disease. Included are descriptions of the most significant AL amyloidosis symptoms as well as addressing burden of disease, including financial concerns,
Mackenzie Boedicker, Isabelle Lousada
openaire +2 more sources
Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis
European Journal of Haematology, 2020Symptomology of AL amyloidosis can be vague, with a broad range of manifestations and potential etiologies. We sought to determine whether time from initial patient‐reported symptom onset to diagnosis was associated with survival.
Amanda Schulman +6 more
semanticscholar +1 more source
Immunomodulatory drugs in AL amyloidosis
Critical Reviews in Oncology/Hematology, 2016Immunoglobulin light chain amyloidosis (AL amyloidosis) is indeed a rare plasma cell disorder, yet the most common of the systemic amyloidoses. The choice of adequate treatment modality is complicated and depends dominantly on the risk stratification of these fragile patients.
Zuzana Kufova +2 more
openaire +3 more sources
Diagnostic score of cardiac involvement in AL amyloidosis.
European Heart Journal-Cardiovascular Imaging, 2020AIMS Early diagnosis of cardiac involvement is a key issue in the management of AL amyloidosis. Our objective was to establish a diagnostic score of cardiac involvement in AL amyloidosis and to compare it with the current consensus criteria [i.e.
M. Nicol +14 more
semanticscholar +1 more source